Table 1.

Baseline characteristics and responses to treatment with rituximab for all subjects grouped according to baseline anti-PLA₂R positivity and clearance versus persistence of anti-PLA₂R at 12 months after treatment

	Age	Gender	Disease Duration (Months)	Serum Creatinine (mg/dl)	Creatinine Clearance (ml/min per 1.73 m²)	Baseline Anti-PLA₂R	12-Month Anti-PLA₂R	Baseline Proteinuria (g/d)	Outcome (12 Months)	Outcome (24 Months)
Group 1: anti-PLA₂R positive; clearance by 12 months
1	40	M	6	1.0	113	31,328	0	11.8	NR	NR
2	60	F	8	1.4	46	28,560	0	8.49	PR	CR
3	53	M	6	1.3	75	25,401	0	8.48	CR	CR
4	44	M	144	1.6	80	25,360	495^e	11.87	NR^f	PR
5	52	M	6	1.5	74	25,067	0	14.69	NR^f	PR
6	38	M	40	0.8	156	24,882	610^e	8.32	PR	PR
7	33	M	5	1.1	109	23,985	0	10.79	CR	CR
8	46	M	8	1.3	81	23,761	280^e	10.09	PR	PR
9	59	M	12	1.1	87	22,462	0	9.88	PR	RL
10	30	M	11	2.1	73	22,251	0	12.12	NR^f	PR
11	51	M	24	2.3	36	21,325	0	16.27	NR	PR
12	47	M	12	1.8	49	20,602	0	14.23	NR^f	PR
13	50	M	12	2.0	46	19,487	0	15.46	PR	PR
14	46	M	60	2.1	61	19,062	0	15.77	PR	CR
15	29	M	4	1.4	49	18,585	0	13.69	NR^f	PR
16	57	F	4	0.8	30	13,506	660^e	8.59	PR	CR
17	64	F	35	1.0	89	9395	0	7.02	PR	PR
Summary	47 ± 10	14:3	11	1.5 ± 0.5	74 ± 32	22,462^a	0^b	11.8
Group 2: anti-PLA₂R positive; persistence at 12 months^c
18	42	M	5	1.0	119	31,994	4710	26.46	NR^f	PR
19	60	M	13	2.6	40	31,425	21,190	20.08	NR	ESRD
20	38	M	10	1.8	68	31,082	16,890	23.44	NR	ΔIST
21	49	M	37	1.4	79	29,381	6361	8.05	NR	ΔIST
22	42	M	17	1.3	83	29,283	20,595	9.88	NR	PR
23	63	M	6	1.5	63	27,041	5725	9.09	NR	ΔIST
24^c	80	M	4	2.0	34	31,091	NA^c	9.95	ΔIST	ΔIST
25^c	45	M	10	1.0	114	21,903	NA^c	8.85	PR	PR
Summary	49 ± 10	6:0	11.5	1.6 ± 0.6	75 ± 26	30,231^a	11,625^b	14.98
Group 3: anti-PLA₂R negative
26	54	M	96	2.30	49	220^d		5.73	PR	PR
27	52	M	6	1.20	145	0^d		7.76	PR	PR
28	37	F	10	0.90	102	0		8.4	PR	CR
29	53	M	13	1.80	58	0		23.54	Died	Died
30	53	M	7	1.80	59	0		16.59	NR	ESRD
31	44	F	8	0.70	116	0		6.1	PR	CR
32	43	M	108	1.90	59	0		12.76	NR	NR^f
33	29	M	5	1.00	126	0		11.33	PR	CR
34	62	M	7	1.40	67	0		19.16	PR	CR
35	42	M	12	1.10	90	0		7.81	PR	PR
Summary	47 ± 10	8:2	9	1.4 ± 0.5	87 ± 34	0		9.86

Baseline and 12-month anti-PLA₂R levels are presented in arbitrary densitometric units. Summary data are presented as means ± standard deviation or medians when appropriate. M, male; F, female; RL, relapse; ΔIST, change in immunosuppressive therapy; NA, not available.
↵Baseline and 12 month anti-PLA₂R levels were significantly lower in group 1 than in group 2 (^aP = 0.001; ^bP < 0.001). There were no other statistically significant differences between groups 1 and 2.
↵^cTwelve-month serum samples were not available for subjects 24 and 25. They are included in group 2 for the purposes of this table, but they are not included in the statistical analyses or the summary data because we were unable to determine if there was a response in anti-PLA₂R or not.
↵^dThese two patients had faint visible bands that fell below the detection threshold of 1000 densitometric units when assayed at 1:25.
↵^eThese bands were undetectable at a 10-second exposure but were visible at longer exposures; the anti-PLA₂R level was extrapolated by calculating percentage of baseline value at the 10-second and longer exposure.
↵^f“Limited” response (>50% decrease from baseline proteinuria but still >3.5 g/d).